jRCTs051240242招募中不适用
Phase II study of carboplatin+nab-paclitaxel+tremelimumab+durvalumab combination therapy for TTF-1 negative advanced non-squamous non-small cell lung cancer (WJOG17223L, TURNING trial)
未提供0 个研究点目标入组 57 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 57
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •The patients written consent will be obtained
- •Patients must be at least 18 years
- •Histologically diagnosed as nonsquamous NSCLC
- •Immunohistochemical staining is negative for TTF1
- •EGFR mutation test and ALK fusion gene result is negative
- •Non radiation curable stage 3, 4 Postoperative recurrence
- •The patient has measurable disease.
- •No symptomatic brain metastases
- •No symptoms of superior vena cava syndrome
- •No spinal cord compression disease
- •No drug therapy for non squamous NSCLC
- •Cases in which drugs that specifically target the checkpoint pathway
- •At the time of enrollment, the specified period of time since completion of the previous treatments or procedures
- •ECOG performance status is 0,1
- •Patients must be free from severe disorders of major organs
- •Expected to survive at least 3 months
- •Weighs at least 30kg.
排除标准
- •Patient has multiple active cancers.
- •Duplication of carcinoma in situ or intramucosal carcinoma equivalent that is considered curable by local treatment shall not be included in the definition of active duplication of carcinoma.
- •Has a local infection or active systemic infection requiring treatment
- •Has active hepatitis B, hepatitis C infection
- •Active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).
- •Interstitial lung disease is evident on computed tomography (CT).
- •Patients with a history of autoimmune disease complicated with active autoimmune disease or requiring steroid therapy or immunosuppressive drugs.
- •Patients with non autoimmune diseases requiring continuous systemic administration (oral or intravenous) of steroids at doses 10 mg/day prednisolone equivalent or patients who used immunosuppressive drugs within 14 days prior to enrollment
- •Patients with symptomatic congestive heart failure, unstable angina, or a history of myocardial infarction within the last year prior to enrollment
- •Patients with the following arrhythmias on electrocardiogram (ECG) and considered clinically serious
- •Patients with gastrointestinal perforation, fistula, or diverticulitis, or with a history of such perforation, fistula, or diverticulitis within 1 year.
- •Patients with uncontrolled peptic ulcer
- •Patients with diabetes uncontrolled by appropriate treatment.
- •Patients with a history of immunotherapy, including durvalumab, tremelimumab, and immuno-antibody therapy, for malignant tumors
- •Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non cancer related conditions (ex. hormone replacement therapy) is acceptable.
- •Patients with a history of severe drug allergy or hypersensitivity to any ingredient or additive of carboplatin or paclitaxel.
- •Patients with Grade 2 or higher peripheral neuropathy
- •Pregnant women, lactating women, women who may be currently pregnant, or patients
- •Patients with clinically problematic psychiatric disorders that would preclude enrollment in the study.
- •Patients who may become a blood donor during the study and within 90 days from the last administration.
- •Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow up period of an interventional study.
- •Any unresolved toxicity NCI CTCAE Grade 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.
- •History of allogenic organ transplantation.
- •History of leptomeningeal carcinomatosis
- •History of active primary immunodeficiency
- •Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.
- •Other patients whose uncontrolled intercurrent illness, including but not limited to above, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent, or are deemed inappropriate by the study investigator or others.
结局指标
主要结局
-
12 month progression free survival rate
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Trial NL77761.056.21Publication withdrawn by sponsorNL-OMON51945CB Pharma24
撤回
不适用
CINCOR* TrialContrast-induced nephropathydisease of the kidneys1001108210029149NL-OMON34043Osprey Medical Inc.25
招募中
不适用
PRECIOUS trialJPRN-UMIN000021514Aichi cancer center hospital370
已完成
1 期
Phase I trial code: PKM17308ISRCTN49135540Sanofi-Aventis Recherche & Développement12
进行中（未招募）
1 期
PPI-Rebound-TrialEUCTR2006-006731-45-DKKøge Sygehus